Cargando…
777. Experience with Liposomal Amphotericin B in Outpatient Parenteral Antimicrobial Therapy (OPAT)
BACKGROUND: While OPAT is known to be a safe, effective, and convenient treatment strategy for patients receiving intravenous antimicrobials in the outpatient setting, the risk of adverse events (AEs) increases when high-risk medications, such as liposomal amphotericin B (L-AMB), are utilized. There...
Autores principales: | Burnett, Yvonne, Hamad, Yasir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811176/ http://dx.doi.org/10.1093/ofid/ofz360.845 |
Ejemplares similares
-
1939. Socioeconomic Predictors of Hospital Readmission in Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients
por: Hamad, Yasir, et al.
Publicado: (2018) -
623. Self-Administered Outpatient Parenteral Antimicrobial Therapy (S-OPAT) in Uninsured Patients
por: Hamad, Yasir, et al.
Publicado: (2020) -
610. Incidence of Acute Kidney Injury in Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients Receiving Vancomycin
por: Hamad, Yasir, et al.
Publicado: (2020) -
Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B
por: van de Peppel, Robert J, et al.
Publicado: (2020) -
OPAT: outpatient parenteral antimicrobial therapy
Publicado: (2020)